Susquehanna International Group, LLP Annovis Bio, Inc. Transaction History
Susquehanna International Group, LLP
- $823 Billion
- Q3 2025
A detailed history of Susquehanna International Group, LLP transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 218,421 shares of ANVS stock, worth $504,552. This represents 0.0% of its overall portfolio holdings.
Number of Shares
218,421
Previous 164,558
32.73%
Holding current value
$504,552
Previous $357,000
25.77%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding ANVS
# of Institutions
49Shares Held
2.03MCall Options Held
167KPut Options Held
97.2K-
Vanguard Group Inc Valley Forge, PA738KShares$1.7 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA184KShares$425,3950.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il174KShares$402,7360.0% of portfolio
-
Northern Trust Corp Chicago, IL121KShares$279,6480.0% of portfolio
-
Black Rock Inc. New York, NY101KShares$232,6370.0% of portfolio
About Annovis Bio, Inc.
- Ticker ANVS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,163,920
- Market Cap $18.9M
- Description
- Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...